An Open-Label Dose-Escalation Phase Ia Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD-101 Injectable in Participants with Advanced Malignant Solid Tumours
Latest Information Update: 22 Dec 2023
At a glance
- Drugs IMD 101 (Primary)
- Indications Bladder cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 22 Dec 2023 New trial record
- 27 Nov 2023 Date of last participant enrolment is 28 Nov 2025 as per Australian New Zealand Clinical Trials Registry